Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
- Autori: Russo, A.; Fratto, M.; Bazan, V.; Schir, V.; Agnese, V.; Cicero, G.; Vincenzi, B.; Tonini, G.; Santini, D.
- Anno di pubblicazione: 2007
- Tipologia: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/27326
The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.